About PharmaCell
PharmaCell is a Healthcare company based in Maastricht (Netherlands) founded in 2005, and was acquired by Lonza in May 2017. Contract development and manufacturing for cell therapies are provided. Its focus areas include Biopharma Outsourcing, CDMO, Biologics and Cell and Gene Therapy.
Company details
PharmaCell is a CMO offering contract development and manufacturing services for Advanced Therapy Medicinal Products such as cellular therapies and regenerative medicine (Tissue culturing).PharmaCell focusses exclusively in cell therapy development and has experience with both autologous and allogenic manufacturing. The company offers its services right from the pre-clinical stage through clinical development and till commercial development and manufacturing. Their service portfolio includes and offers cell culturing process development, fill and finish, Quality Control (QC)-testing and Good Manufacturing Practices (GMP) production services, as well as storage and distribution of clinical trial materials and GMP and regulatory consultancy. The company signed a 3-year services agreement with US-based oncology firm Lion Biotechnologies to supply cancer cell therapies, in April 2017.
- Headquarters Maastricht, Netherlands
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website pharmacell.nl
- Social LinkedIn Facebook
- Acquired by Lonza (May 2017)
Funding Insights of PharmaCell
- Total Rounds 2
- Last Round Grant — $503,850
- Investors Count 2
All 2 funding rounds of PharmaCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2016 | $503,850 | Grant | – | – | |
| Jun 2007 | Seed | – | Brightlands Venture Partners | – |
3 investors in total: 3 institutional.
Investors in PharmaCell
PharmaCell has secured backing from 3 investors, including institutional and venture fund investors. Prominent investors backing the company include Lonza, European Union and Brightlands Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Brightlands Venture Partners is focused on venture capital investments. | brightlandsventurepartners.com | Geleen, Netherlands | ||
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
CDMO services for pharma, biotech, and specialty ingredients are provided. | 1897 | lonza.com | Basel, Switzerland |
Investor details for PharmaCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of PharmaCell
4 dated milestones of PharmaCell across 12 years, from founding to its latest funding, stage changes and deals.
- Founded PharmaCell is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $504K.
- Exit Acquired by Lonza.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about PharmaCell
PharmaCell was founded in 2005 and raised its 1st funding round 2 years after it was founded.
PharmaCell is headquartered in Maastricht, Netherlands. It is registered at Maastricht, Limburg, Netherlands.
PharmaCell is a CMO offering contract development and manufacturing services for Advanced Therapy Medicinal Products such as cellular therapies and regenerative medicine (Tissue culturing).PharmaCell focusses exclusively in cell therapy development and has experience with both autologous and allogenic manufacturing. The company offers its services right from the pre-clinical stage through clinical development and till commercial development and manufacturing. Their service portfolio includes and offers cell culturing process development, fill and finish, Quality Control (QC)-testing and Good Manufacturing Practices (GMP) production services, as well as storage and distribution of clinical trial materials and GMP and regulatory consultancy. The company signed a 3-year services agreement with US-based oncology firm Lion Biotechnologies to supply cancer cell therapies, in April 2017.
PharmaCell has 3 investors. Key investors include Lonza, European Union, and Brightlands Venture Partners.
Yes. PharmaCell was acquired by Lonza in May 2017.